Teva and mAbxience partner to develop biosimilar candidate for oncology

Teva and mAbxience partner to develop biosimilar candidate for oncology

Submitted by admin on October 4, 2024 - 9:28am
Source: 
Pharmaceutical Technology
News Tags: 
Teva Pharmaceutical
mAbxience
oncology
biosimilars
Headline: 
Teva and mAbxience partner to develop biosimilar candidate for oncology
snippet: 

Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.

Do Not Allow Advertisers to Use My Personal information